The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|February 3, 2017
Monitoring the Emergence of T790M in EGFR-Mutated Lung Cancer
Author(s)Hatim Husain, MD
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence of<em> T790M </em>in <em>EGFR</em>-mutated non-small cell lung cancer (NSCLC).
Advertisement
Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses a study monitoring the emergence ofT790MinEGFR
Advertisement
Related to this article
Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.
A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.
First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.
ARROS-1 data show zidesamtinib drives 94% responses in untreated ROS1+ NSCLC, including brain metastases, supporting first-line FDA filing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
3
Mosunetuzumab Combo Improves PFS in R/R Follicular Lymphoma
4
FDA Launches Expedited IND Pilot to Speed First-in-Human Trials
5